Interested in using our technology? Feel free to send us a proposal here.

TESTIMONIALS   FAQ   VIDEOS   JOBS

Dr. Philip Low
Founder, Chairman & CEO, NeuroVigil, Inc

Philip Low is Chairman, Chief Scientific Officer and Chief Executive Officer of NeuroVigil. He is the inventor, neurotechnologist and computational neuroscientist responsible for the SPEARS algorithm, the iBrain neural monitor and the Cambridge Declaration on Consciousness. At the University of Chicago, he invented novel neurosurgical techniques. At Harvard Medical School, he showed in 9 weeks that a collagen inhibitor could successfully neutralize the growth of fibroid tumors — he was 19 years old at the time. At the Salk Institute, which he joined at the recommendation of the late Francis Crick, Nobel Laureate of DNA fame, and where he was a Sloan-Swartz, Swartz and Kavli fellow, he invented the SPEARS algorithm and authored a doctoral dissertation which overturned long-standing beliefs regarding the nature of human and animal neural sleep patterns and made possible the automated and non-invasive single channel detection of REM sleep, cortical and subcortical patterns, providing the foundation for iBrain and the Cambridge Declaration on Consciousness, which recognized the overwhelming neurobiological similarities between human and non-human animals. The actual PhD thesis, a dynamic map of brain activity derived from a single non-invasive EEG channel, was one page long and was unanimously approved by a committee including four members of the National Academy of Sciences and two past Presidents of the Society for Neuroscience. His work has been featured in technical and popular articles including The Proceedings of the National Academy of Sciences, CNN, The Economist, The New York Times and TIME.

While still in his twenties, Dr. Low was appointed to dual appointments at the Stanford School of Medicine and the MIT Media Lab and was named President of the 1st International Congress on Alzheimer's Disease and Advanced Neurotechnologies, held in Monaco in February 2010. Dr. Low also chaired the first Francis Crick Memorial Conference in Cambridge, UK, in 2012 and is an advisor to the White House and the US-Israel Science and Technology Foundation on matters of Neuroscience, Health and Technology. To bring his innovations to the market, Dr. Low founded NeuroVigil, the neurodiagnostics company responsible for iBrain, a wireless portable neural monitoring and analytics platform, used by the Pharmaceutical Industry, Government and Academia to monitor non-invasively and remotely neuropathologies such as Alzheimer's, Autism, Depression, Epilepsy, Gulf War Syndrome, OCD, Parkinsons's, PTSD, TBI and Rett Syndrome, as well as the response of drugs affecting the brain, and to restore loss of function, such as communication, including in ALS patients. Dr. Low founded NeuroVigil when he was still in graduate school and enlisted several Nobel Laureates and Fortune 100 company founders. Under Dr. Low's leadership, NeuroVigil won the 2008 DFJ Venture and UCSD Entrepreneur Challenges, successfully launched the first outpatient clinical trial for a CNS drug in 2009, won the CONNECT Most Innovative New Product in the Life Sciences Award in 2010, closed a financing round at an unprecedented seed valuation on May 1st 2011, began a partnership with Stephen Hawking on Brain Based Communication systems, was recognized by The Washington Post and Fast Company as one the Top 10 Most Innovative Companies in Health Care, alongside GE and the Cleveland Clinic, and in 2012, its "sleep mining technology" was listed by The New York Times as one of "32 Innovations that Will Change Your Tomorrow". He holds numerous patents and three "extraordinary ability" clearances from the US government, is a 2010 MIT Technology Review TR-35 Top Young Innovator, an honor shared with the Founders of Google, Linux and Facebook, became in 2011, the Inaugural Jacobs-Rady Pioneer for Global Innovation and Entrepreneurship, awarded every five years to an outstanding tech innovator and Chairman/CEO, and was singled out in 2013 by The Scientist Magazine as "A Scientist to Watch".

Legal Counsel


Mr. Ian Feinberg has over 30 years of extensive experience in handling trials, binding arbitrations, and trial preparation of, and counseling (including litigation avoidance) regarding patent, copyright, trade secret, trademark, licensing, unfair competition, and antitrust matters, particularly in the software and semiconductor industries. He obtained his J.D. at Stanford Law School in 1979, where he made Law Review. He graduated Phi Beta Kappa from Stanford with a B.A. in Economics, with distinction in 1976. He was admitted to the California Bar in 1979 and served on the United States District Courts for Northern, Southern, Central and Eastern Districts of California, the United States District Court of Arizona and United States Court of Appeals for the Ninth Circuit. Ian is one of six NeuroVigil outside counsels. Ian has assisted NeuroVigil in successful licensing transactions and contracts with the Salk Institute and Hoffman - La Roche. Source: Feinberg Day Alberti & Thompson LLP


Mr. Richard Ben-Veniste first achieved national prominence during the mid-1970s, when he served as one of the lead prosecutors on the Watergate Special Prosecution Force. He has been a key figure in some of the nation's most significant governmental activities at the intersection of law and politics. From 1995 to 1996, for example, he acted as Chief Counsel (Minority) of the Senate Whitewater Committee; from 1976 to 1977, he was Special Outside Counsel for the Senate Subcommittee on Governmental Operations; and from 1973 to 1975, he held the position of Chief of the Watergate Special Prosecutor's Watergate Task Force. From 2003 to 2004, Richard served as one of ten commissioners on the bipartisan 9-11 Commission. Most recently, in 2009 he served on a task force created by the Secretary of the Department of Homeland Security to assess the national alert system and make recommendations for improvement. Prior to joining Mayer Brown in 2002, Richard was a partner at Weil Gotshal & Manges LLP and Ben-Veniste and Shernoff. From 1968 to 1973 he served as Assistant US Attorney for the Southern District of New York where he was Chief of the Special Prosecutions Section. Richard has been listed in Who's Who in America since 1975, The Best Lawyers in America since 1983, and Washingtonian Magazine's Top Lawyers in Washington, DC since 1992, when the list first appeared. Richard holds a JD from Columbia University Law School where he was a Harlan Fiske Stone Scholar, an LLM from Northwestern University, and an honorary LLD as well as a B.A., Magna Cum Laude, from Muhlenberg College. Source: Mayer Brown, LLP


Mr. Jeffrey N. Gibbs has represented health care companies on FDA-related matters since 1984. He advises companies on a wide variety of issues, including product approvals, marketing, clinical studies, and enforcement. Previously, he served in the Chief Counsel's Office of the U.S. Food and Drug Administration, where he became an Associate Chief Counsel for Enforcement. While at FDA, Mr. Gibbs received the FDA Award of Merit. He also was appointed a Special Assistant United States Attorney for the District of Columbia. Before joining FDA, he clerked for a United States District Court Judge in the District of New Jersey. Mr. Gibbs has written and lectured extensively on a variety of FDA-related topics. Mr. Gibbs served as a member of the Editorial Advisory Board for the Food and Drug Law Journal from 1998 to 2004, and was Chair in 2003-2004. He is currently on the editorial advisory board of IVD Technology and Guide to Good Clinical Practices, and is a member of the Human Subjects Research Board for George Mason University. Mr. Gibbs serves as Secretary and General Counsel of the Board of Directors of the Food and Drug Law Institute. He is a graduate of Princeton University (1975 summa cum laude) and the New York University School of Law (1978 with honors). He is admitted to practice law in the District of Columbia. Source: Hyman, Phelps & McNamara, LLP

NeuroVigil has several other experienced attorneys on staff for Corporate and IP matters not disclosed here.